BURLINGTON, Ontario--(BUSINESS WIRE)--Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company revolutionizing drug delivery through innovation, today announced the successful receipt of their cannabis sales license from Health Canada following a rigorous application and inspection process. This is in addition to the micro-processing license received November 15, 2019 which has allowed RDT to offer white-label products to multiple Canadian producers.
“Today marks another successful achievement at RDT with the receipt of our cannabis sales license from Health Canada and we are very pleased to be able to offer Canadian patients and cannabis consumers our innovative branded products,” said Mark Upsdell, CEO, Rapid Dose Therapeutics. “The novel dosing and delivery of our QuickStrip and QuickSip products makes them ideal for use by a wide range of consumers and we see a tremendous opportunity to leverage our technology with a number of key targets, in both the recreational and medical markets including long-term care and assisted living.”
The first marketed RDT cannabis product, a 10 mg THC lined QuickSips, will be distributed soon to cannabis stores across Ontario followed shortly thereafter by the RDT QuickStrip 10 mg THC sublingual oral dissolving strip. RDT has entered into a Master Distribution Agreement with CannMart Inc. (formerly Namaste Technologies Inc.) now Lifeist (TSXV: N), (FRANKFURT: M5BQ), (OTCMKTS: NXTTF) for the exclusive sales and distribution of RDT-branded cannabis products into retail locations across Canada.